Prostate Cell News 10.25 July 12, 2019 | |
| |
TOP STORYPC3 prostate cancer cells with CRISPR/Cas9-mediated G protein-coupled receptor class C group 5 member A (GPRC5A) knockout (KO) exhibited significantly reduced cell proliferation both in vitro and in vivo. RNA-seq revealed that GPRC5AKO PC3 cells had dysregulated expression of cell cycle-related genes, leading to cell cycle arrest at the G2/M phase. [Int J Cancer] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists addressed the question whether changes in breast cancer susceptibility gene 2 (BRCA2) expression, a potential surrogate marker for BRCA2 activity, may affect the response of castration-resistant prostate cancer cells to 6-thioguanine, a thiopurine used in the treatment of hematological malignancies. [Cancers] Full Article The tumor-tropic capacity of RAW264.7 cells towards RM-1 mouse prostate cancer cells did not undergo significant change after drug loading in vitro and in vivo. [J Nanobiotechnology] Full Article Researchers explored the biological functions of small nucleolar RNA host gene 12 (SNHG12) and investigated the interaction between miR-133b and SNHG12 in the progression of prostate cancer (PCa). They detected SNHG12 expression level in PCa cells and tissues, and then analyzed its clinical significance, which revealed that SNHG12 has the potential to predict prognosis of PCa. [J Cell Physiol] Abstract Overexpression of miR-139 in prostate cancer cells led to a significant reduction in cell proliferation and migration compared with control cells, with cells arrested in G2 of cell cycle. Examination of the molecular mechanism of growth inhibition by miR-139 revealed the downregulation of activated AKT and cyclin D1, with upregulation of the CDK inhibitor p21. [Prostate] Abstract The androgen receptor pathway was confirmed to be an upstream regulation signaling pathway of PSLNR by transcriptionally regulating its expression in androgen-dependent prostate cancer (PCa) cells. PSLNR also significantly inhibited PCa proliferation by inducing cell apoptosis in a p53-dependent manner. [Prostate] Abstract Investigators report the biological evaluation of the polychlorinated biphenyl 28 derived OH-metabolites 3-OHCB28 or 3′-OHCB28 in prostate cancer cells. Depending on concentration, both metabolites inhibited the growth of PC3 cells. In addition 3′-OHCB28 reduced the necessary concentration of abiraterone required for the inhibition of PC3 cells by a factor of four. [Invest New Drugs] Abstract The authors found that polymethoxyflavonoid (PMF) 2 inhibited the growth of LNCaP cells more strongly than PMF1, and it was less cytotoxic against the normal human prostate RWPE-1 cells. PMF2 upregulated Bad and Bax, downregulated Bcl-2, and activated caspase-3 and PARP in LNCaP cells, thereby inducing apoptosis. PMF2 also suppressed anchorage-independent growth of LNCaP cells. [AAPS J] Abstract PC-3 cells were treated with silymarin-enriched extract, silibinin, silychristine, alone, and in combination with doxorubicin, and cell proliferation was assessed by the MTT assay. Cell cycle, apoptosis, and autophagy rate were assessed by flow cytometry. Expression levels of autophagy-related genes were quantified by qRT-PCR, ELISA and western blot while transmission electron microscopy was performed to reveal autophagic structures. [Planta Med] Abstract Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSSingle-Cell RNA Sequencing in Cancer: Lessons Learned and Emerging Challenges The authors discuss some of the common themes emerging from initial studies of single-cell RNA sequencing in cancer and then highlight challenges in cancer biology for which emerging single-cell genomics methods may provide a compelling approach. [Mol Cell] Full Article Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSSengenics announced that it has joined the Foundation for the National Institutes of Health Biomarkers Consortium. As a member of the consortium, Sengenics aims to further accelerate the identification and commercialization of autoantibody biomarkers for early diagnosis of cancer and autoimmune diseases as well as development of new companion diagnostics tests. [Sengenics] Press Release Keeping Do-It-Yourself Gene Science Safe Two Case Western Reserve University faculty members have received a two-year grant to provide regulatory recommendations for gene-editing research conducted in non-traditional settings. The aim of this $160,000 grant from the National Human Genome Research Institute at the National Institutes of Health is to protect the public while encouraging creativity and innovation that could benefit many people. [Case Western Reserve University] Press Release | |
| |
POLICY NEWSResearchers in the University of California system lost subscription access to the major publisher Elsevier, the result of a closely watched fight between the two parties over how academic research should get read and paid for. [STAT News] Editorial Sweden Passes Law For National Research Misconduct Agency After several high-profile cases, the country’s government is creating a board to oversee and investigate all serious allegations of scientific misconduct. [The Scientist] Editorial Hungarian Government Takes Control of Research Institutes despite Outcry After months of struggle between Hungary’s research ministry and its scientific community, the nation’s parliament ratified a law on 2 July that gives the government control over the 40 or so institutes belonging to the Hungarian Academy of Sciences. The government says that its aim is to make research more innovative. [Nature News] Editorial
| |
EVENTSNEW Advanced Cell Therapies and Tissue Engineering Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Researcher – Genitourinary Cancers (CCTI Columbia University) NEW Senior Endowed Professorship – Cellular Principles & Evolution (Stony Brook University) Research Scientist – Prostate Cancer Progression & Resistance (MD Anderson Cancer Center) Postdoctoral Position – Prostate Biology (University of Washington) Postdoctoral Scientist – Prostate Organoids (Rutgers Cancer Institute of New Jersey) Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California) Postdoctoral Fellow – Nanomedicine in Prostate Cancer (Queen’s University Belfast) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|